See more : Energiedienst Holding AG (0QOH.L) Income Statement Analysis – Financial Results
Complete financial analysis of Loews Corporation (L) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Loews Corporation, a leading company in the Insurance – Property & Casualty industry within the Financial Services sector.
You may be interested
- Umbra Applied Technologies Group, Inc. (UATG) Income Statement Analysis – Financial Results
- Mandom Corporation (MDOMF) Income Statement Analysis – Financial Results
- Uponor Oyj (UPONOR.HE) Income Statement Analysis – Financial Results
- Randolph Bancorp, Inc. (RNDB) Income Statement Analysis – Financial Results
- Citius Pharmaceuticals Inc (CTXRW) Income Statement Analysis – Financial Results
Loews Corporation (L)
About Loews Corporation
Loews Corporation provides commercial property and casualty insurance in the United States and internationally. The company offers specialty insurance products, such as management and professional liability, and other coverage products; surety and fidelity bonds; property insurance products that include property, marine and boiler, and machinery coverages; and casualty insurance products, such as workers' compensation, general and product liability, and commercial auto and umbrella coverages. It also provides loss-sensitive insurance programs; and warranty, risk management, information, and claims administration services. The company markets its insurance products and services through independent agents, brokers, and managing general underwriters. In addition, the company is involved in the transportation and storage of natural gas and natural gas liquids(NGLs), and hydrocarbons through natural gas pipelines covering approximately 13,615 miles of interconnected pipelines; 450 miles of NGL pipelines in Louisiana and Texas; 14 underground storage fields with an aggregate gas capacity of approximately 213 billion cubic feet of natural gas; and eleven salt dome caverns and related brine infrastructure for providing brine supply services. Further, the company operates a chain of 26 hotels; and develops, manufactures, and markets a range of extrusion blow-molded and injection molded plastic containers for customers in the pharmaceutical, dairy, household chemicals, food/nutraceuticals, industrial/specialty chemicals, and water and beverage/juice segments, as well as manufactures commodity and differentiated plastic resins from recycled plastic materials. Loews Corporation was incorporated in 1969 and is headquartered in New York, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 | 1985 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 15.68B | 14.04B | 14.12B | 13.79B | 14.93B | 14.07B | 13.74B | 13.11B | 13.42B | 14.33B | 15.05B | 14.55B | 14.13B | 14.62B | 14.12B | 13.25B | 18.38B | 17.91B | 16.02B | 15.24B | 16.46B | 17.50B | 19.42B | 21.34B | 21.47B | 21.21B | 20.14B | 20.44B | 18.68B | 13.52B | 13.69B | 13.69B | 13.62B | 12.64B | 11.44B | 10.87B | 9.32B | 8.63B | 6.32B |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 15.68B | 14.04B | 14.12B | 13.79B | 14.93B | 14.07B | 13.74B | 13.11B | 13.42B | 14.33B | 15.05B | 14.55B | 14.13B | 14.62B | 14.12B | 13.25B | 18.38B | 17.91B | 16.02B | 15.24B | 16.46B | 17.50B | 19.42B | 21.34B | 21.47B | 21.21B | 20.14B | 20.44B | 18.68B | 13.52B | 13.69B | 13.69B | 13.62B | 12.64B | 11.44B | 10.87B | 9.32B | 8.63B | 6.32B |
| Gross Profit Ratio | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.98B | 4.26B | 3.55B | 3.16B | 1.85B | 1.53B | 1.51B | 1.28B | 1.07B | 1.13B | 992.00M | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.55B | 1.39B | 0.00 | 1.19B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 3.38B | 3.05B | 2.96B | 3.92B | 4.85B | 4.81B | 4.67B | 4.16B | 0.00 | 0.00 | 0.00 | 0.00 | 1.55B | 1.39B | 0.00 | 1.19B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.98B | 4.26B | 3.55B | 3.16B | 1.85B | 1.53B | 1.51B | 1.28B | 1.07B | 1.13B | 992.00M | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Expenses | 12.30B | 3.08B | -15.62B | -19.08B | -18.85B | 12.66B | 11.51B | 11.63B | 12.65B | 12.02B | 11.91B | 11.62B | 9.83B | 9.81B | 10.90B | 10.44B | -17.05B | -13.66B | 13.64B | -13.15B | -17.30B | -15.69B | -19.85B | -20.21B | -25.03B | -24.99B | -23.06B | -22.69B | -19.43B | -14.59B | -14.39B | -15.09B | -13.41B | -12.74B | -11.46B | -9.50B | -8.52B | -7.92B | -5.64B |
| Operating Expenses | 15.68B | 3.08B | -15.62B | -19.08B | -18.85B | 12.66B | 11.51B | 11.63B | 12.65B | 12.02B | 11.91B | 11.62B | 11.38B | 11.20B | 10.90B | 11.62B | -17.05B | -13.66B | 13.64B | -13.15B | -17.30B | -15.69B | -19.85B | -20.21B | -21.05B | -20.73B | -19.52B | -19.53B | -17.57B | -13.06B | -12.88B | -13.81B | -12.33B | -11.60B | -10.47B | -9.50B | -8.52B | -7.92B | -5.64B |
| Cost & Expenses | 15.68B | 12.66B | 11.94B | 15.26B | 13.81B | 13.23B | 12.15B | 12.17B | 13.17B | 12.52B | 13.62B | 13.15B | 11.90B | 11.71B | 12.39B | 12.66B | 13.81B | 13.44B | 14.17B | 13.42B | 17.84B | 15.85B | 20.23B | 18.13B | 20.52B | 20.13B | 18.55B | 18.03B | 15.84B | 13.25B | 1.67B | 1.43B | 11.42B | 10.77B | 9.54B | 127.60M | 140.60M | 101.40M | 31.20M |
| Interest Income | 0.00 | 378.00M | 424.00M | 515.00M | 591.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 14.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 376.00M | 378.00M | 424.00M | 515.00M | 591.00M | 574.00M | 646.00M | 536.00M | 520.00M | 498.00M | 442.00M | 440.00M | 522.00M | 517.00M | 448.00M | 345.00M | 318.00M | 304.10M | 364.20M | 324.10M | 308.40M | 309.60M | 332.00M | 356.90M | 354.30M | 369.20M | 323.40M | 318.00M | 282.50M | 174.60M | 162.30M | 148.80M | 163.60M | 171.60M | 130.90M | 127.60M | 140.60M | 101.40M | 31.20M |
| Depreciation & Amortization | 1.74B | 1.71B | 1.61B | 1.65B | 1.69B | 1.66B | 874.00M | 841.00M | 955.00M | 899.00M | 871.00M | 905.00M | 833.00M | 816.00M | 585.00M | 393.00M | 221.00M | -8.00M | 174.50M | 329.30M | 192.00M | 139.00M | 58.70M | -13.90M | 298.00M | 219.70M | 226.50M | 107.40M | 84.40M | 40.70M | 39.80M | 11.00M | -45.00M | -24.80M | -235.50M | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | 3.99B | 3.07B | 4.21B | -215.00M | 3.40B | 3.06B | 3.10B | 2.31B | 1.72B | 3.21B | 2.65B | 2.74B | 2.96B | 3.52B | 2.96B | 1.62B | 5.40B | 5.18B | 2.59B | 2.50B | -644.40M | 1.94B | -373.80M | 1.11B | 1.60B | 1.67B | 2.14B | 2.83B | 3.21B | 492.18M | 297.40M | 159.80M | 118.60M | 146.80M | -104.60M | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA Ratio | 25.44% | 8.27% | -7.02% | -33.02% | -19.93% | 16.00% | 20.78% | 17.18% | 12.61% | 17.07% | 15.07% | 15.13% | 20.92% | 24.06% | 13.76% | 39.82% | 8.42% | 23.66% | 13.99% | 15.87% | -3.91% | 11.10% | -1.93% | 5.22% | 3.31% | 3.30% | 4.21% | 4.98% | 6.36% | 3.64% | 6.16% | -0.78% | 9.11% | 8.00% | 6.42% | 12.54% | 8.59% | 8.15% | 10.76% |
| Operating Income | 2.21B | 652.00M | -1.51B | -5.29B | -3.92B | 1.34B | 1.98B | 1.41B | 737.00M | 1.55B | 1.40B | 1.30B | 2.12B | 2.70B | 1.36B | 4.88B | 1.33B | 4.25B | 2.07B | 2.09B | -836.40M | 1.80B | -432.50M | 1.13B | 412.00M | 479.50M | 621.70M | 910.50M | 1.10B | 451.48M | 803.00M | -117.30M | 1.29B | 1.04B | 969.50M | 1.36B | 800.80M | 702.70M | 680.40M |
| Operating Income Ratio | 14.07% | 4.64% | -10.67% | -38.34% | -26.25% | 9.51% | 14.42% | 10.76% | 5.49% | 10.79% | 9.28% | 8.91% | 15.02% | 18.47% | 9.61% | 36.85% | 7.21% | 23.71% | 12.90% | 13.71% | -5.08% | 10.31% | -2.23% | 5.28% | 1.92% | 2.26% | 3.09% | 4.45% | 5.90% | 3.34% | 5.87% | -0.86% | 9.44% | 8.19% | 8.48% | 12.54% | 8.59% | 8.15% | 10.76% |
| Total Other Income/Expenses | -210.00M | -10.02B | -9.52B | -1.46B | -8.96B | -8.43B | -7.49B | -8.01B | -13.17B | -12.52B | 3.20B | -1.01B | -520.00M | -517.00M | -2.51B | -3.38B | -701.00M | -141.60M | -213.90M | -203.10M | -1.38B | 1.67B | -764.50M | 2.01B | 532.20M | 597.90M | 971.50M | 1.50B | 1.74B | 266.10M | 689.36M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax | 2.00B | 1.38B | 2.18B | -1.46B | 1.12B | 834.00M | 1.58B | 936.00M | 244.00M | 1.81B | 1.43B | 1.40B | 2.23B | 2.90B | 1.73B | 587.00M | 4.58B | 4.47B | 1.85B | 1.82B | -1.38B | 1.65B | -813.10M | 3.21B | 944.20M | 1.08B | 1.59B | 2.41B | 2.84B | 266.15M | 5.82B | 2.84B | 5.98B | 5.30B | 4.98B | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | 12.73% | 9.83% | 15.46% | -10.61% | 7.49% | 5.93% | 11.52% | 7.14% | 1.82% | 12.64% | 9.49% | 9.61% | 15.80% | 19.86% | 12.25% | 4.43% | 24.89% | 24.97% | 11.53% | 11.95% | -8.37% | 9.41% | -4.19% | 15.02% | 4.40% | 5.08% | 7.91% | 11.78% | 15.20% | 1.97% | 42.55% | 20.73% | 43.92% | 41.91% | 43.50% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 451.00M | 278.00M | 479.00M | -173.00M | 248.00M | 128.00M | 170.00M | 220.00M | -43.00M | 457.00M | 360.00M | 289.00M | 536.00M | 895.00M | 345.00M | 7.00M | -1.48B | 1.45B | 490.40M | 533.80M | -534.10M | 582.20M | -175.40M | -1.11B | -305.50M | -354.50M | -495.30M | -791.40M | -945.30M | 9.04M | 46.60M | -388.70M | 217.50M | 59.00M | -68.50M | 325.90M | -36.00M | 55.80M | 60.20M |
| Net Income | 1.43B | 822.00M | 1.56B | -1.29B | 932.00M | 636.00M | 1.16B | 654.00M | 260.00M | 591.00M | 595.00M | 568.00M | 1.06B | 1.29B | 564.00M | 4.53B | 2.49B | 2.49B | 1.21B | 1.23B | -610.70M | 912.00M | -589.10M | 1.88B | 363.20M | 464.80M | 793.60M | 1.38B | 1.77B | 267.83M | 594.10M | 122.60M | 904.30M | 804.70M | 907.10M | 908.50M | 696.20M | 545.50M | 589.00M |
| Net Income Ratio | 9.15% | 5.85% | 11.06% | -9.36% | 6.24% | 4.52% | 8.47% | 4.99% | 1.94% | 4.13% | 3.95% | 3.90% | 7.53% | 8.81% | 4.00% | 34.20% | 13.54% | 13.91% | 7.56% | 8.08% | -3.71% | 5.21% | -3.03% | 8.80% | 1.69% | 2.19% | 3.94% | 6.77% | 9.45% | 1.98% | 4.34% | 0.90% | 6.64% | 6.37% | 7.93% | 8.36% | 7.47% | 6.32% | 9.32% |
| EPS | 6.30 | 3.39 | 6.08 | -4.61 | 3.08 | 1.99 | 3.46 | 1.93 | 0.76 | 1.55 | 1.53 | 1.44 | 2.69 | 3.08 | 1.30 | 9.05 | 3.66 | 3.75 | 1.72 | 1.88 | -1.10 | 1.64 | -1.03 | 3.10 | 0.56 | 0.68 | 1.15 | 1.99 | 2.50 | 0.37 | 0.77 | 0.15 | 1.10 | 0.92 | 1.01 | 1.00 | 0.75 | 0.56 | 0.61 |
| EPS Diluted | 6.29 | 3.38 | 6.06 | -4.61 | 3.07 | 1.99 | 3.45 | 1.93 | 0.72 | 1.55 | 1.53 | 1.43 | 2.63 | 3.07 | 1.30 | 9.05 | 3.65 | 3.75 | 1.72 | 1.88 | -1.10 | 1.64 | -1.00 | 3.10 | 0.56 | 0.68 | 1.15 | 1.99 | 2.50 | 0.37 | 0.77 | 0.15 | 1.10 | 0.92 | 1.01 | 1.00 | 0.75 | 0.56 | 0.61 |
| Weighted Avg Shares Out | 227.48M | 242.83M | 259.67M | 280.32M | 302.70M | 319.06M | 336.61M | 337.95M | 339.90M | 381.92M | 388.64M | 395.12M | 396.20M | 418.72M | 432.81M | 477.23M | 534.79M | 552.68M | 557.10M | 556.50M | 556.35M | 564.93M | 574.47M | 591.69M | 650.51M | 686.90M | 690.09M | 697.18M | 707.22M | 723.78M | 769.09M | 800.37M | 825.42M | 875.55M | 901.99M | 912.45M | 933.34M | 975.08M | 971.85M |
| Weighted Avg Shares Out (Dil) | 227.81M | 243.28M | 260.20M | 280.32M | 303.35M | 319.93M | 337.50M | 338.31M | 362.69M | 382.55M | 389.51M | 395.87M | 405.32M | 419.52M | 433.45M | 477.23M | 536.00M | 553.54M | 557.97M | 556.50M | 556.35M | 564.93M | 587.07M | 591.69M | 666.67M | 689.45M | 690.09M | 699.12M | 707.82M | 726.50M | 773.15M | 800.37M | 825.42M | 875.55M | 901.99M | 912.45M | 933.34M | 975.08M | 971.85M |
Akeso's Cadonilimab (PD-1/CTLA-4 Bispecific Antibody) Combination Therapy for PD-(L)1 Resistant NSCLC Showcased in Oral Presentation at 2024 Asian Conference on Lung Cancer
HONG KONG , Dec. 4, 2024 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced the results from a prospective, open-label, single-arm, multi-center phase Ib/II clinical study (AK104-IIT-018) of cadonilimab (PD-1/CTLA-4 bispecific antibody) in patients with advanced or metastatic...
LOEWS CORPORATION ANNOUNCES QUARTERLY DIVIDEND ON COMMON STOCK
NEW YORK , Nov. 12, 2024 /PRNewswire/ -- Loews Corporation (NYSE: L) announced today the declaration of the Company's quarterly dividend of $0.0625 per share of Common Stock, payable December 10, 2024 to shareholders of record as of the close...
LOEWS CORPORATION REPORTS NET INCOME OF $401 MILLION FOR THE THIRD QUARTER OF 2024
NEW YORK , Nov. 4, 2024 /PRNewswire/ -- Loews Corporation (NYSE: L) today released its third quarter 2024 financial results. Third Quarter 2024 highlights: Loews Corporation reported net income of $401 million, or $1.82 per share, in the third quarter...
Loews Corporation to Release Third Quarter 2024 Results on November 4, 2024
NEW YORK , Oct. 15, 2024 /PRNewswire/ -- Loews Corporation (NYSE: L) will report third quarter 2024 financial results on Monday, November 4, 2024. On that date the Company will also post earnings remarks on its website.
Loews Arlington Selects ROH to Streamline Sales Operations and Payment Processing
NEW YORK--(BUSINESS WIRE)-- #SaaS--ROH, the hospitality industry's first payments and revenue management platform designed to help hotels increase profitability, today announced that Loews Arlington has selected ROH to streamline its sales operations. With increased visibility and less manual work, sales...
FDA approves Roche's Tecentriq Hybreza, the first and only subcutaneous anti-PD-(L)1 cancer immunotherapy
Basel, 13 September 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Tecentriq HybrezaTM (atezolizumab and hyaluronidase-tqjs), the first and only PD-(L)1 inhibitor for subcutaneous (SC), under the skin...
FDA Approves Genentech's Tecentriq Hybreza, the First and Only Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Tecentriq Hybreza™ (atezolizumab and hyaluronidase-tqjs), the first and only PD-(L)1 inhibitor for...
Loews Corporation Announces Favorable Resolution of Boardwalk Pipelines Acquisition Litigation
NEW YORK , Sept. 9, 2024 /PRNewswire/ -- Loews Corporation (NYSE: L) announced today that the Delaware Court of Chancery found no liability in connection with Loews's 2018 acquisition of the minority limited partner interests in its Boardwalk Pipelines subsidiary.
LOEWS CORPORATION ANNOUNCES QUARTERLY DIVIDEND ON COMMON STOCK
NEW YORK , Aug. 6, 2024 /PRNewswire/ -- Loews Corporation (NYSE: L) announced today the declaration of the Company's quarterly dividend of $0.0625 per share of Common Stock, payable September 3, 2024 to shareholders of record as of the close...
3 Holding Company Stocks to Buy Other Than Berkshire Hathaway
I'm a big fan of Berkshire Hathaway (NYSE: BRK-A , BRK-B ) and Warren Buffett. As a result, I've become a big fan of holding company stocks.
Source: https://incomestatements.info
Category: Stock Reports